Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Parabolic Drugs

BSE:533211
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
533211
BSE
₹65M
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Parabolic Drugs Limited develops, manufactures, and sells active pharmaceutical ingredients (API) and API intermediates in India. The last earnings update was 599 days ago. More info.


Add to Portfolio Compare Print
  • Parabolic Drugs has significant price volatility in the past 3 months.
533211 Share Price and Events
7 Day Returns
0%
BSE:533211
7.7%
IN Pharmaceuticals
-3.9%
IN Market
1 Year Returns
-41.7%
BSE:533211
-15%
IN Pharmaceuticals
-32.2%
IN Market
533211 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Parabolic Drugs (533211) 0% -11% -65.3% -41.7% -87.8% -90.6%
IN Pharmaceuticals 7.7% -10.3% -8.7% -15% -24.2% -35.1%
IN Market -3.9% -26.8% -31.7% -32.2% -23.8% -14.9%
1 Year Return vs Industry and Market
  • 533211 underperformed the Pharmaceuticals industry which returned -15% over the past year.
  • 533211 underperformed the Market in India which returned -32.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

533211 Value

 Is Parabolic Drugs undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Parabolic Drugs is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Parabolic Drugs has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Parabolic Drugs. This is due to cash flow or dividend data being unavailable. The share price is ₹1.05.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Parabolic Drugs's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Parabolic Drugs's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BSE:533211 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-03-31) in INR Not available
BSE:533211 Share Price ** BSE (2020-03-31) in INR ₹1.05
India Pharmaceuticals Industry PE Ratio Median Figure of 109 Publicly-Listed Pharmaceuticals Companies 11.66x
India Market PE Ratio Median Figure of 2,614 Publicly-Listed Companies 9.41x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Parabolic Drugs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Parabolic Drugs, we can't compare the value of its earnings to the India market.
Price based on expected Growth
Does Parabolic Drugs's expected growth come at a high price?
Raw Data
BSE:533211 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
India Pharmaceuticals Industry PEG Ratio Median Figure of 27 Publicly-Listed Pharmaceuticals Companies 1.03x
India Market PEG Ratio Median Figure of 400 Publicly-Listed Companies 0.8x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Parabolic Drugs, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Parabolic Drugs's assets?
Raw Data
BSE:533211 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-03-31) in INR Not available
BSE:533211 Share Price * BSE (2020-03-31) in INR ₹1.05
India Pharmaceuticals Industry PB Ratio Median Figure of 135 Publicly-Listed Pharmaceuticals Companies 1.07x
India Market PB Ratio Median Figure of 3,613 Publicly-Listed Companies 0.63x

* Primary Listing of Parabolic Drugs.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Examine Parabolic Drugs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Parabolic Drugs's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Parabolic Drugs's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Parabolic Drugs has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

533211 Future Performance

 How is Parabolic Drugs expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Parabolic Drugs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.3%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Parabolic Drugs expected to grow at an attractive rate?
  • Unable to compare Parabolic Drugs's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Parabolic Drugs's earnings growth to the India market average as no estimate data is available.
  • Unable to compare Parabolic Drugs's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BSE:533211 Future Growth Rates Data Sources
Data Point Source Value (per year)
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 25.3%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 9.6%
India Market Earnings Growth Rate Market Cap Weighted Average 19.2%
India Market Revenue Growth Rate Market Cap Weighted Average 8.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BSE:533211 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BSE:533211 Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2018-03-31 732 31 -575
2017-03-31 749 32 -1,081
2016-03-31 768 897 -4,857

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Parabolic Drugs is high growth as no earnings estimate data is available.
  • Unable to determine if Parabolic Drugs is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BSE:533211 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Parabolic Drugs Company Filings, last reported 2 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:533211 Past Financials Data
Date (Data in INR Millions) EPS *
2018-03-31 -9.30
2017-03-31 -17.46
2016-03-31 -78.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Parabolic Drugs will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Parabolic Drugs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Parabolic Drugs's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Parabolic Drugs's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Parabolic Drugs's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Parabolic Drugs has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

533211 Past Performance

  How has Parabolic Drugs performed over the past 5 years?

  • Parabolic Drugs's last earnings update was 599 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Parabolic Drugs's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if Parabolic Drugs's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Parabolic Drugs's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare Parabolic Drugs's 1-year growth to the IN Pharmaceuticals industry average as past earnings data has not been reported.
Earnings and Revenue History
Parabolic Drugs's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Parabolic Drugs Company Filings, last reported 2 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:533211 Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-03-31 731.57 -575.48 99.36
2017-03-31 749.01 -1,080.86 92.88
2016-03-31 768.35 -4,856.99 111.81
2015-03-31 2,321.41 -3,804.48 185.77
2014-03-31 4,379.06 -1,337.98 381.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if Parabolic Drugs has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if Parabolic Drugs has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if Parabolic Drugs improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Parabolic Drugs's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Parabolic Drugs has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

533211 Health

 How is Parabolic Drugs's financial health and their level of debt?

In this section we usually analyse Parabolic Drugs's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Parabolic Drugs has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.

Show me the analysis anyway

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Parabolic Drugs's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as Parabolic Drugs has not reported sufficient balance sheet data.
  • Unable to establish if Parabolic Drugs's long term commitments exceed its cash and other short term assets as Parabolic Drugs has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of Parabolic Drugs's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if Parabolic Drugs has a high level of physical assets or inventory without balance sheet data.
  • Parabolic Drugs has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Parabolic Drugs Company Filings, last reported 2 years ago.

BSE:533211 Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-03-31 -8,553.44 9,830.29 8.69
2017-03-31 -7,977.96 9,783.77 6.41
2016-03-31 -6,897.10 9,713.95 7.28
2015-03-31 -2,040.11 9,572.88 31.96
2014-03-31 1,762.72 8,418.10 60.63
  • Parabolic Drugs has no debt.
  • Parabolic Drugs currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • Parabolic Drugs has no debt, it does not need to be covered by operating cash flow.
  • Parabolic Drugs has no debt, therefore coverage of interest payments is not a concern.

Next steps:

  1. Take a look at our analysis of 533211’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. Parabolic Drugs's cash and debt levels may be found in its annual reports archived here.
  3. Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Parabolic Drugs's financial data was last updated here.
  4. Companies with strong financial health are considered a less risky investment. Discover these stocks here.
  5. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Financial health checks
We assess Parabolic Drugs's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Parabolic Drugs has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

533211 Dividends

 What is Parabolic Drugs's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Parabolic Drugs dividends.
If you bought ₹2,000 of Parabolic Drugs shares you are expected to receive ₹0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Parabolic Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Parabolic Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BSE:533211 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 77 Stocks 1%
India Market Average Dividend Yield Market Cap Weighted Average of 1419 Stocks 2%
India Minimum Threshold Dividend Yield 10th Percentile 0.4%
India Bottom 25% Dividend Yield 25th Percentile 1%
India Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BSE:533211 Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2013-09-10 0.000 0.000
2012-08-16 0.250 3.270
2011-08-16 0.500 1.750

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Parabolic Drugs has not reported any payouts.
  • Unable to verify if Parabolic Drugs's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Parabolic Drugs's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Parabolic Drugs has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Parabolic Drugs's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Parabolic Drugs afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Parabolic Drugs has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

533211 Management

 What is the CEO of Parabolic Drugs's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pranav Gupta
COMPENSATION ₹0
AGE 52
TENURE AS CEO 11.6 years
CEO Bio

Mr. Pranav Gupta, M.B.A., B. Tech. (Mechanical) has been the Managing Director of Parabolic Drugs Ltd. since September 1, 2008 and as its Compliance Officer since February 13, 2018. Mr. Gupta drives the overall management of Parabolic. He has been involved with Parabolic Drugs as a Promoter since its inception and is actively involved in the day to day operations of Parabolic specifically overlooking after production, finance and technology related areas. He gained vital exposure to international markets and best management practices. Mr. Gupta worked with Ford Motor Co. of USA. He has been the Chairman of Parabolic Drugs Ltd. since February 13, 2013 and its Director since November 01,1997. Mr. Gupta is the member of the executive committee of the Punjab Chapter of PHD Chambers of Commerce. He is the Founder and served as President of St. John Old Boys School Association (SJOBA). He serves as Secretary of the SJOBA said Foundation. Mr. Gupta also serves as an Executive member of TIE Chapter, Chandigarh. He holds a bachelors' degree in technology (mechanical engineering) from Thapar Engineering College, Patiala and is a Bachelor in Technology (Mechanical Engineering) from Indian Institute of Technology, Delhi and M.B.A. degree from University of Kansas, USA.

CEO Compensation
  • No earnings data for Parabolic Drugs, not possible to compare to compensation.
  • Pranav's remuneration is lower than average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Parabolic Drugs management team in years:

8.7
Average Tenure
53.5
Average Age
  • The average tenure for the Parabolic Drugs management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Pranav Gupta

TITLE
Chairman
AGE
52
TENURE
11.6 yrs

Vineet Gupta

TITLE
Whole- Time Director
AGE
50

Ramesh Singh

TITLE
Vice President of Operations
COMPENSATION
₹700K
AGE
60

Raghuvir Goyal

TITLE
Vice President of Finance & Accounts
COMPENSATION
₹1M
AGE
62
TENURE
3.8 yrs

Yatish Bansal

TITLE
President of Technical

Ranjit Marwah

TITLE
Senior Vice President of Human Resources & Administration
COMPENSATION
₹979K
AGE
52

Vipin Gupta

TITLE
Vice President
COMPENSATION
₹120K
TENURE
8.7 yrs

Ravinder Singh

TITLE
Senior General Manager of Purchase & Materials
COMPENSATION
₹982K
AGE
55

A. Sabharwal

TITLE
Consultant
Board of Directors Tenure

Average tenure and age of the Parabolic Drugs board of directors in years:

5.7
Average Tenure
52
Average Age
  • The tenure for the Parabolic Drugs board of directors is about average.
Board of Directors

Pranav Gupta

TITLE
Chairman
AGE
52
TENURE
7.2 yrs

Vineet Gupta

TITLE
Whole- Time Director
AGE
50
TENURE
11.6 yrs

Jagjit Chahal

TITLE
Independent & Non-Executive Director
AGE
68
TENURE
5.7 yrs

Vandana Singla

TITLE
Independent & Non-Executive Director
AGE
56
TENURE
5.4 yrs

Sanjeev Kumar

TITLE
Independent Non-Executive Director
AGE
34
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
X
Management checks
We assess Parabolic Drugs's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Parabolic Drugs has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

533211 News

Simply Wall St News

533211 Company Info

Description

Parabolic Drugs Limited develops, manufactures, and sells active pharmaceutical ingredients (API) and API intermediates in India. The company offers oral and sterile semi synthetic penicillin APIs; oral and sterile cephalosporin APIs in antibiotic area; non-antibiotic APIs for cardiovascular, NSAID, anti-hypertensive, and osteoporosis therapeutic areas; and calcium sennoside, colchicine, raubasine, reserpine, thiocolchicoside, vinpocetine, and yohimbine. It also provides custom research and manufacturing services to pharma companies, including research and development, and manufacturing services for NCE and generics; IPR support for process design and infringement guidance; and QA, QC, and regulatory support for meeting quality and documentation requirements. The company also exports its products to approximately 51 countries. Parabolic Drugs Limited was founded in 1996 and is based in Chandigarh, India.

Details
Name: Parabolic Drugs Limited
533211
Exchange: BSE
Founded: 1996
₹64,986,614
61,892,014
Website: http://www.parabolicdrugs.com
Address: Parabolic Drugs Limited
S.C.O. 186-187,
Second Floor,
Chandigarh,
Chandigarh, 160008,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 533211 Equity Shares Mumbai Stock Exchange IN INR 01. Jul 2010
NSEI PARABDRUGS Equity Shares National Stock Exchange of India IN INR 01. Jul 2010
Number of employees
Current staff
Staff numbers
0
Parabolic Drugs employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 13:57
End of day share price update: 2020/03/31 00:00
Last earnings filing: 2018/08/14
Last earnings reported: 2018/03/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.